ALNOV:EPA
Novacyt SA
€0.44
arrow_downward
-1.12%(-0.0050) 1D
Oct 30, 5:35:10 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.44
High
€0.44
Low
€0.44
Mkt. cap
30.51M
Avg. vol.
195.23K
Volume
47.41K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
Open
€0.44
High
€0.44
Low
€0.44
Mkt. cap
30.51M
Avg. vol.
195.23K
Volume
47.41K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
24/7 Wall St.
·
7 hours ago
S&P Says Meta Can’t Make Money From AI as Well as Its Rivals
TradingView
·
9 hours ago
Nifty 500 vs S&P 500: India or US, innovation is the only game in town for investors
www.tokenpost.com
·
5 hours ago
Tech sell-off opens scope for a short-term rebound as oil tests S&P 500 uptrend
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA